Mouse Monoclonal GRM6 Antibody

The GRM6 antibody targets the metabotropic glutamate receptor 6 (mGluR6), a class C G protein-coupled receptor predominantly expressed in the retina's ON-bipolar cells. As a member of group III metabotropic glutamate receptors (mGluRs), GRM6 plays a critical role in synaptic signal transduction by modulating glutamate neurotransmission. It couples with the Gi/o protein pathway, inhibiting cyclic nucleotide-gated channels in response to glutamate release from photoreceptors, thereby regulating visual processing under low-light conditions. Dysfunction of GRM6 is linked to congenital stationary night blindness (CSNB), a non-progressive retinal disorder characterized by impaired night vision. Research on GRM6 antibodies focuses on elucidating receptor localization, expression patterns, and pathophysiological mechanisms in retinal diseases. These antibodies are also used in diagnostic assays to identify GRM6 mutations or aberrant expression in clinical samples. Additionally, GRM6 has emerged as a potential therapeutic target for neurological and neuropsychiatric disorders, though most applications remain preclinical. The development of specific GRM6 antibodies aids in advancing understanding of retinal signaling pathways and evaluating targeted therapies for vision-related conditions.